186 related articles for article (PubMed ID: 32423565)
1. Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel.
Kalra S; Ghosh S; Das AK; Nair T; Bajaj S; Priya G; Mehrotra RN; Das S; Shah P; Deshmukh V; Chawla M; Sanyal D; Chandrasekaran S; Khandelwal D; Joshi A; Eliana F; Permana H; Fariduddin MD; Shrestha PK; Shrestha D; Kahandawa S; Sumanathilaka M; Shaheed A; Rahim AA; Orabi A; Al-Ani A; Hussein W; Kumar D; Shaikh K
Indian Heart J; 2020; 72(1):7-13. PubMed ID: 32423565
[TBL] [Abstract][Full Text] [Related]
2. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a
Cefalu WT; Kaul S; Gerstein HC; Holman RR; Zinman B; Skyler JS; Green JB; Buse JB; Inzucchi SE; Leiter LA; Raz I; Rosenstock J; Riddle MC
Diabetes Care; 2018 Jan; 41(1):14-31. PubMed ID: 29263194
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
[TBL] [Abstract][Full Text] [Related]
5. Glucodynamics and glucocracy in type 2 diabetes mellitus: clinical evidence and practice-based opinion on modern sulfonylurea use, from an International Expert Group (South Asia, Middle East & Africa) via modified Delphi method.
Kalra S; A K D; Md F; K S; P S; A A R; M J; S S; A O; M R S; Selim S; M P B; Gangopadhyay KK; Y A L; T N; D D; S D T; V D; Dutta D; H K; R M; S D; A D; A B; G P; S C; Dhingra A; N P; A AA; M M
Curr Med Res Opin; 2021 Mar; 37(3):403-409. PubMed ID: 33319626
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
Varin EM; McLean BA; Lovshin JA
Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
[TBL] [Abstract][Full Text] [Related]
7. Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group.
Kalra S; Das AK; Baruah MP; Unnikrishnan AG; Dasgupta A; Shah P; Sahay R; Shukla R; Das S; Tiwaskar M; Vijayakumar G; Chawla M; Eliana F; Suastika K; Orabi A; Rahim AAA; Uloko A; Bahendeka S; Abdela AA; Mohammed F; Pathan F; Rahman MH; Afsana F; Selim S; Moosa M; Murad M; Shreshtha PK; Shreshtha D; Giri M; Hussain W; Al-Ani A; Ramaiya K; Singh S; Raza SA; Aye TT; Garusinghe C; Muthukuda D; Weerakkody M; Kahandawa S; Bavuma C; Ruder S; Vanny K; Khanolkar M; Czupryniak L
Diabetes Ther; 2019 Oct; 10(5):1577-1593. PubMed ID: 31267358
[TBL] [Abstract][Full Text] [Related]
8. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
9. Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG.
Tsioufis C; Andrikou E; Thomopoulos C; Papanas N; Tousoulis D
Curr Vasc Pharmacol; 2017; 15(5):457-468. PubMed ID: 27928947
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
11. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
Ludwig L; Darmon P; Guerci B
Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data.
Bain S; Druyts E; Balijepalli C; Baxter CA; Currie CJ; Das R; Donnelly R; Khunti K; Langerman H; Leigh P; Siliman G; Thorlund K; Toor K; Vora J; Mills EJ
Diabetes Obes Metab; 2017 Mar; 19(3):329-335. PubMed ID: 27862902
[TBL] [Abstract][Full Text] [Related]
14. Sulfonylureas: do we need to introspect safety again?
Sehra D; Sehra S; Sehra ST
Expert Opin Drug Saf; 2011 Nov; 10(6):851-61. PubMed ID: 21605015
[TBL] [Abstract][Full Text] [Related]
15. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S146-S155. PubMed ID: 29693361
[TBL] [Abstract][Full Text] [Related]
16. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
17. A review of cardiovascular outcome trials in type 2 diabetes.
Cypryk K; Małecki P
Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209802
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors.
Sachinidis A; Nikolic D; Stoian AP; Papanas N; Tarar O; Rizvi AA; Rizzo M
Metabolism; 2020 Oct; 111():154343. PubMed ID: 32810485
[TBL] [Abstract][Full Text] [Related]
20. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
